ViiV Healthcare's Juluca shows sustained treatment effect in studies
Apr. 3, 2019 7:45 AM ET|About: GlaxoSmithKline plc (GSK)|By: Mamta Mayani, SA News Editor
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
Tue April 2, 2019 2:58 PM|GlobeNewswire|About: BCTXF, INCY, MRK
BERKELEY, Calif., and VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF),
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
Wed April 3, 2019 7:00 AM|GlobeNewswire|About: EDIT
– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology –
– Collaboration enables Editas Medicine (EDIT) to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers –
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.,
BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
AstraZeneca's Fasenra successful in mid-stage HES study
Apr. 4, 2019 7:21 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
Roche's ipatasertib shows encouraging action in early-stage breast cancer study
Apr. 1, 2019 12:00 PM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor
Amgen (AMGN) Presents At Oppenheimer's 29th Annual Healthcare Conference - Slideshow
Apr. 1, 2019 1:34 PM ET | About: Amgen Inc. (AMGN)
Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
Tue April 2, 2019 7:00 AM|PR Newswire|About: BHC
Shipments to U.S. Pharmaceutical Distributors Begin
BRIDGEWATER, N.J., April 2, 2019 /PRNewswire
Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.
Mon April 1, 2019 4:30 PM|PR Newswire|About: JNJPR Newswire
NEW BRUNSWICK, N.J., April 1, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash.
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
Tue April 2, 2019 8:30 AM|Business Wire|About: CLVS
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Mon April 1, 2019 6:55 AM|Business Wire|About: MRK
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK),
Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Mon April 1, 2019 6:30 AM|Business Wire|About: MRK
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas
Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck (MRK)
KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
PR Newswire
DUBLIN, April 1, 2019 /PRNewswire/ -- Alkermes plc (ALKS)
Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis
Mon April 1, 2019 7:00 AM|PR Newswire|About: BHC
Investigational Treatment Demonstrated Promising Results in Preclinical Studies
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/
ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer
Mon April 1, 2019 8:00 AM|Business Wire|About: ADXS
Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS)
European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
April 1, 2019 Osaka, JAPAN
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”)
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
Fri March 29, 2019 7:44 AM|Business Wire|About: BLUE
Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Fri March 29, 2019 8:00 AM|Business Wire|About: SGEN
-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) (Nasdaq:SGEN)
http://www.seattlegenetics.com/pipeline/tisotumab-vedotin
http://www.genmab.com/product-pipeline/products-in-development/humax-tf-adc
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
Fri March 29, 2019 8:12 AM|Business Wire|About: CELG
European advisory group backs expanded use of Sanofi's Mozobil
Mar. 29, 2019 8:32 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor
Starboard pulls out of Celgene fight
Mar. 29, 2019 12:22 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Thu March 28, 2019 4:15 PM|GlobeNewswire|About: NBIX, VYGR
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)
Basel, March 27, 2019 Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mar 27, 2019
AstraZeneca leads in the development of a new International Life Science Innovation Park in China
PUBLISHED27 March 2019
Cluster to be built by the Wuxi municipal government and Wuxi High-tech District
AstraZeneca, Daiichi Sankyo ink $6.9B cancer deal
Mar. 29, 2019 3:33 AM ET|About: AstraZeneca PLC (AZN)|By: Yoel Minkoff, SA News Editor
https://www.daiichisankyo.com/rd/pipeline/pdf/20190131_Pipeline_EN.pdf
Bolstering its oncology push, AstraZeneca (NYSE:AZN) has struck a deal worth up to $6.9B to sell and develop Daiichi Sankyo's (OTCPK:DSNKY) promising new cancer drug.
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
First DARZALEX combination treatment regimen being pursued in the frontline setting for transplant eligible patients with multiple myeloma
RARITAN, NJ, March 26, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson
Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019
Wed March 27, 2019 6:06 AM|Business Wire|About: GILD
Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S.
Wed March 27, 2019 4:49 PM|PR Newswire|About: JNJPR Newswire
JACKSONVILLE, Fla., March 27, 2019 /PRNewswire/ -- Johnson & Johnson Vision
Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
Thu March 28, 2019 8:30 AM|GlobeNewswire|About: SRPT
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA®(canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
If approved, INVOKANA® will be the first and only therapy in nearly 20 years indicated to reduce the risk of end-stage kidney disease when added to current standard of care
Submission is based on data from the landmark Phase 3 CREDENCE renal outcomes study, which stopped early for positive efficacy findings
Raritan, N.J., March 28, 2019
Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
Thu March 28, 2019 7:00 AM|Business Wire|About: SGEN
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)
http://www.seattlegenetics.com/pipeline/enfortumab-vedotin
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Tue March 26, 2019 8:30 AM|Business Wire|About: GILD
Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues
Tue March 26, 2019 2:00 AM|Business Wire|About: ILMN
Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results
Tue March 26, 2019 8:00 AM|PR Newswire|About: JNJPR Newswire
JACKSONVILLE, Fla., March 26, 2019 /PRNewswire/ -- Johnson & Johnson
Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
Mon March 25, 2019 4:15 PM|Business Wire|About: VCYT
Biogen and Eisai launch late-stage study of BAN2401 in Alzheimer's
Mar. 22, 2019 9:12 AM ET|About: Biogen Inc. (BIIB)|By: Douglas W. House, SA News Editor
AstraZeneca's Forxiga OK'd in Europe for T1D
Mar. 25, 2019 7:04 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Tue March 26, 2019 1:00 AM|PR Newswire|About: ABBV
BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
Tue March 26, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK
https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform
Tue March 26, 2019 7:00 AM|Business Wire|About: AZN
SAN DIEGO--(BUSINESS WIRE)-- Ichor® Medical Systems, Inc. (Ichor)
British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET™ on its Formulary
Fri March 22, 2019 10:29 AM|Canada Newswire|About: ABBV
J&J files European marketing application for expanded use of Darzalex
Mar. 22, 2019 8:22 AM ET|About: Celgene Corporation (CELG)|By: Douglas W. House, SA News Editor
Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing
Sun March 24, 2019 8:30 PM|PR Newswire|About: TMO
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
Mon March 25, 2019 7:30 AM|GlobeNewswire|About: SRPT
Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Fri March 22, 2019 10:19 AM|GlobeNewswire|About: GALT
NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (GALT)
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina
Fri March 22, 2019 8:00 AM|Business Wire|About: BLUE
BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
Wed March 20, 2019 4:05 PM|GlobeNewswire|About: BCTXF, MRK
BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
Thu March 21, 2019 7:30 AM|Business Wire|About: NVCR
Abiomed reports 6% stake in ShockWave Medical
Mar. 21, 2019 6:55 AM ET|About: ABIOMED, Inc. (ABMD)|By: Douglas W. House, SA News Editor
Viking Therapeutics (VKTX) Investor Presentation - Slideshow
Mar. 21, 2019 3:12 PM ET | About: Viking Therapeutics, Inc. (VKTX)
Sorrento Therapeutics (SRNE) Presents At Oppenheimer 29th Annual Healthcare Conference - Slideshow
Mar. 21, 2019 2:29 PM ET|1 comment | About: Sorrento Therapeutics, Inc. (SRNE)
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
Fri March 22, 2019 7:30 AM|Business Wire|About: NVCR
INNOVATE-3
https://www.novocure.com/novocure-initiates-phase-3-pivotal-trial-in-recurrent-ovarian-cancer/
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics
Wed March 20, 2019 6:45 AM|Business Wire|About: PFE
Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022
Wed March 20, 2019 6:30 AM|Business Wire|About: MRK
Novo files two U.S. applications for oral semaglutide
Mar. 20, 2019 11:07 AM ET|About: Novo Nordisk A/S (NVO)|By: Douglas W. House, SA News Editor
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
Wed March 20, 2019 6:30 AM|Business Wire|About: ALXN
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology
Wed March 20, 2019 8:45 AM|PR Newswire|About: LLY
PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (LLY)
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients
Tue March 19, 2019 8:00 AM|PR Newswire|About: ABT
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -
DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN
New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer
Mon March 18, 2019 8:00 AM|Canada Newswire|About: MRK
Abbott's next-gen LVAD shows treatment benefit in comparative study
Mar. 18, 2019 10:32 AM ET|About: Abbott Laboratories (ABT)|By: Douglas W. House, SA News Editor
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Tue March 19, 2019 7:00 PM|Business Wire|About: SAGE
First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes
Mon March 18, 2019 9:01 AM|Business Wire|About: AZN
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
Mon March 18, 2019 8:00 AM|PR Newswire|About: ARRY
BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY)
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
Mon March 18, 2019 9:15 PM|Business Wire|About: RHHBY
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
18 March 2019 07:00 GMT
New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device
Sun March 17, 2019 9:00 AM|PR Newswire|About: ABT
Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter
Sun March 17, 2019 11:00 AM|PR Newswire|About: BSX
Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
Sat March 16, 2019 12:45 PM|Business Wire|About: CLVS
Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference
Mon March 18, 2019 7:30 AM|Business Wire|About: NVCR
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ:NVCR)
Stryker acquires OrthoSpace, Ltd.
03/14/2019
Kalamazoo, Michigan, March 14, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today it has completed the acquisition of OrthoSpace, Ltd., a privately held company founded in 2009 and headquartered in Caesarea, Israel, in an all cash transaction for an upfront payment of $110 million and future milestone payments of up to an additional $110 million.
Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device
Thu March 14, 2019 1:52 PM|PR Newswire|About: ABT
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Fri March 15, 2019 4:00 PM|PR Newswire|About: AMGN
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Fri March 15, 2019 7:40 PM|GlobeNewswire|About: SNY
France, March 16, 2019 (GLOBE NEWSWIRE)
Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)
Fri March 15, 2019 9:00 AM|PR Newswire|About: JNJPR Newswire
SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, March 15, 2019 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)
U.S. FDA Clears da Vinci SP for Certain Transoral Otolaryngology Procedures
Fri March 15, 2019 1:36 PM|GlobeNewswire|About: ISRGGlobeNewswire
SUNNYVALE, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Intuitive (ISRG)
https://www.intuitive.com/en-us/products-and-services/da-vinci/systems/sp
Basel, 15 March 2019
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
Roche (SIX: RO, ROG; OTCQX: RHHBY)
Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
Wed March 13, 2019 7:00 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and BRIDGEWATER, N.J., March 13, 2019 /PRNewswire/
Hemispherx Bio up 8% on Ampligen progress
Mar. 13, 2019 10:39 AM ET|About: Hemispherx Biopharma, ... (HEB)|By: Douglas W. House, SA News Editor
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Thu March 14, 2019 6:45 AM|Business Wire|About: MRK
Johnson & Johnson files U.S. marketing application for expanded use of Darzalex
Mar. 12, 2019 4:52 PM ET|About: Celgene Corporation (CELG)|By: Douglas W. House, SA News Editor
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
Tue March 12, 2019 4:30 PM|Business Wire|About: CELG
FDA OKs new generic version of Novartis' Diovan
Mar. 12, 2019 3:56 PM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
Editas Medicine (EDIT) Investor Presentation - Slideshow
Mar. 12, 2019 3:52 PM ET | About: Editas Medicine, Inc. (EDIT)
Princeton faculty to test new Microsoft Station B platform toward goal of boosting production of lifesaving biological therapies
by the Office of CommunicationsMarch 12, 2019 9:19 a.m.
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Tue March 12, 2019 9:56 PM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and WASHINGTON, March 12, 2019 /PRNewswire/
Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Tue March 12, 2019 6:45 AM|PR Newswire|About: LLY
Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations
Tue March 12, 2019 5:07 AM|Business Wire|About: VRTX
Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia
Tue March 12, 2019 8:00 AM|PR Newswire|About: NBIX
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mon March 11, 2019 3:45 PM|PR Newswire|About: REGN, SNY
* In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin
PR Newswire
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/
Microsoft researchers have spent years studying those underlying processes and learning how to influence them. Now they are launching collaborations with Princeton University and UK-based companies Oxford Biomedica and Synthace to develop and test an integrated platform that’s designed to help other companies and research teams perform that work more reliably. The goal: To reduce the amount of trial and error required to make beneficial scientific breakthroughs and enable companies and academic researchers already established in the field to operate more efficiently and cost-effectively.
The project, called Station B, aims to develop an end-to-end platform — including a software stack, a means to automate lab experiments and machine learning methods that run in the cloud on Microsoft Azure — to help scientists more efficiently and predictably channel the power of life’s ultimate information processing machines: living cells.
Mar 11, 2019
CAMBRIDGE, United Kingdom – In recent years, companies have figured out how to engineer bacteria to make cement, helping reduce the pollution involved in traditional manufacturing. Using more advanced techniques, scientists have even programmed patients’ immune cells to recognize and kill leukemia cells, giving children who had virtually no chance of survival years of prolonged life.
Bristol-Myers sends open letter to shareholders supporting rationale for Celgene merger
Mar. 6, 2019 7:17 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Fri March 8, 2019 12:06 PM|Business Wire|About: RHHBY
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Mon March 11, 2019 7:30 AM|PR Newswire|About: AGN
Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic -
PR Newswire
DUBLIN, March 11, 2019 /PRNewswire/ -- Allergan plc (AGN)
Seres teams up with AstraZeneca in cancer; shares up 17%
Mar. 11, 2019 9:48 AM ET|About: Seres Therapeutics, Inc. (MCRB)|By: Douglas W. House, SA News Editor
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Fri March 8, 2019 12:59 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and PARIS, March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi
Roche's Tecentriq + Avastin OK'd in Europe for first-line lung cancer
Mar. 8, 2019 7:11 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor
https://www.tecentriq-hcp.com/nsclc.html
Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
Fri March 8, 2019 5:00 AM|PR Newswire|About: SGMO
Bayer files European application for darolutamide for prostate cancer
Mar. 8, 2019 7:02 AM ET|About: Bayer A.G. ADR (BAYRY)|By: Douglas W. House, SA News Editor
Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve
Fri March 8, 2019 9:05 AM|Business Wire|About: ALXN
Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from Pixabay
Powered by GoDaddy Website Builder